Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
2025 Mar 11;16:1548346
Jalandra R, Dalal N, Yadav AK, Verma D, Sharma M, Singh R, Khosla A, Kumar A, Solanki PR
If your current telehealth provider works with Belmar, the switch is usually seamless
Commenting over Lupin upcoming launches in the US, the CEO stated, that the target launch date for Rituximaba therapy for blood canceris set for June 2026." Meanwhile, at the call, Ramesh Swaminathan, Global CFO, Lupin, informed that the company expects its diagnostics business to achieve breakeven EBITDA by the end of this year (2025).
* The overall YoY revenue growth is expected to improve over the next three years, with a meaningful increase expected in FY29
US$ 27.20
US$ 27.63
US$ 25.41
US$ 22.28
US$ 29.34
